​​​Note: This is preliminary data, and the 1-year data set will continue to be reviewed and analyzed with additional details to be shared as available. The refractive error change and axial length change standard deviation were ±0.39 and ±0.12 respectively.

Published real-world data indicates Year 2 myopia progression data likely to trend closely with Year 1 values.

Combined with the 6-year data previously published in Clinical Ophthalmology in 2022, and the analysis from 3 independent studies released in September, the one-year data suggests NaturalVue Multifocal may effectively manage eye growth and refractive error change among children.

This information may describe uses for this product, i.e., Myopia Progression Control, which have not been approved by the FDA for use in the United States. It is intended for educational purposes only. NaturalVue® Multifocal is part of an ongoing clinical trial (RCT) that is studying its effectiveness for myopia progression control.

Global Specialty Lens Symposium

January 17-20, 2024
Las Vegas, NV

Download the PROTECT Factsheet

Email
Registration

* PROgressive Myopia Treatment Evaluation for NaturalVue Multifocal Contact Lens Trial

This information may describe uses for this product, i.e., Myopia Progression Control, which have not been approved by the FDA for use in the United States. It is intended for educational purposes only. NaturalVue® Multifocal is part of an ongoing clinical trial (RCT) that is studying its effectiveness for myopia progression control. 

NATURALVUE® INDICATIONS FOR USE
NaturalVue® (etafilcon A) Multifocal 1 Day Disposable Soft Contact Lenses are indicated for daily wear for the correction of refractive ametropia (myopia and hyperopia), and/or presbyopia, and myopia progression control in normal eyes.